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Summary 
We have established fetal liver-derived T cell receptor (TCR)T/t~ +  , CD3 + T cell lines that are 
cytotoxic for maternal T cells. Fetal liver-derived lymphoid progenitors yielded predominantly 
TCR-'y//~ + cell clusters when cultured on fetal bone marrow-derived stromal cells in the presence 
of a cytokine cocktail under magnetic force. These tightly adherent dusters were cloned by limiting 
dilution and the resulting cell lines analyzed for phenotype and function. Six of eight TCtL-'y/I~ 
lines from 8-9.5-wk gestation fetuses were V#2 + as compared with zero of eight lines from 
later stages of gestation (10 and 15 wk), where all the lines were V~I+. In cytotoxicity assays, 
these TCR-T//~ +,  CD3 +,  CD4-,  and CD8 + or  CDS-  long-term cultured lymphoid cells 
(LLC) were killer cells active against the class I antigens on maternal T cells. Of the cell lines, 
the CD8 + TCR-7,//~ + LLC had the highest levels of killer activity.  Thus fetal liver TCR-'y/~ § 
T cells may play a crucial role in protection against invading maternal T cells generated in the 
feto-maternal interaction. 
T 
he development and function of fetal lymphocytes is of 
particular interest in terms of feto-maternal immuno- 
logic interactions. In recent years, we have found cytotoxic 
fetal antibodies that react against maternal alloreactive T cells 
(1-3).  We have further demonstrated that fetal CTLs can be 
generated by the stimulation of maternal alloreactive  T cells (3). 
In recent years, two types of heterodimeric forms of TCR 
have been defined. TCR-oUfl and TCR-'y/~ (4-6). Although 
the precise function of TCR-3'/8 + cells is not yet known, 
TCR-~//# +  cells  can  recognize Ag  in  a  MHC-restricted 
manner (7), undergo TCR-mediated cell activation (8), and 
participate in immune surveillance at the epithelial cell sur- 
face (9). 
CD7 +, CD4-, CDS-, and CD3-  T cell precursors enter 
the human thymus at 7-8 wk of gestation and begin to ex- 
press CD2 Ag intrathymically (10, 11). Expression of CD2 
molecules by immature thymocytes before expression of sur- 
face CD3 molecules suggests the involvement of CD2 mole- 
cules in triggering immature TCR-negative thymocytes (12, 
13). The TCR-B and -~ epitopes are first expressed at 9.5 wk 
of gestation.  TCR-8 + cells comprise only a minority of fetal 
thymocytes throughout ontogeny with the highest percentage 
(11%) seen at 9.5 wk of gestation. In contrast, the percentage 
of TCR-~ + cells (surface and cytoplasmic) increases from 
0%  at 8.5 wk to 91% at  15 wk of gestation (14). 
A variety of cytokines such as IL-2 (15), IL-3 (16, 17), and 
II,5 (18-20)  are involved in lymphoid cell development. In 
addition, stromal cells are essential for the growth and differen- 
tiation of lymphoid cells (21). In our present study, we have 
developed a magnetic culture system that can promote the 
growth of human lymphoid precursors in the presence of sev- 
eral such cytokines and bone marrow-derived stromal cells 
(BMST)  1. This culture system has made it possible to grow 
fetal lymphoid precursors for 6 mo or longer and obtain long- 
term cultured lymphoid cells (LLC) derived from a single 
duster. We have determined cellular characteristics and func- 
tional properties of both TCIL-~///~  +  and TCR-oUB  +  fetal 
liver-derived  T-LLC. 
Materials and Methods 
Preparation of Fetal Samples.  Fetal  bone marrow and liver were 
obtained from the Department of Clinical Pathology of Shinshu 
1 Abbreviations used in thispaper:  BMST, bone marrow-derived stromal cells; 
LLC, long-term cultured lymphoid cells; TLFA, T lymphocytotoxic  human 
fetal antibodies. 
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abortions or at the time of  surgery for ectopic  pregnancy.  The gesta- 
tional age ranged from 8 to 15 wk as determined by crown-rump 
length and menstrual records. The fetal specimens  were placed  into 
heparinized cold HBSS, and vigorously mixed with a  rubber 
policeman and through a metal mesh. The bone marrow cell sus- 
pensions were diluted with heparinized cold HBSS, layered over 
40% Percoll density gradients, and centrifuged at 2,000 g for 20 
min at 4~  Ceils of the 40% fraction were washed twice with 
cold HBSS and used as sources of BMST. Stromal actin was de- 
tected with the CGA-7 mAb (Enzo Diagnostic, New York) and 
the antigen-positive calls were treated as described below for the 
expansion of BMST. The liver cell suspensions were layered over 
a 60% Percoll density gradient, centrifuged, and then cells from 
the 60% fraction were washed with cold HBSS. Contaminating 
mature lymphocytes were removed  by treating 2  x  106 cells with 
2 x  107 anti-CD2 and anti-CD19 coated Dynabeads (Dynal A. S., 
Oslo, Norway). CD34 § ceils were then isolated using anti-CD34 
coated Dynabeads. The  purified CD34 + cells were collected, 
washed with cold HBSS, and used as sources of lymphoid pro- 
genitors. 
Magnetic Cell Culture System.  A newly designed magnetic cub 
ture system was employed here. The system consisted of magnetic 
alloy tablets (400-1,800 gauss). To grow original cytokine-induced 
BMST, ceUs of the 40% Percoll fraction (1-2 x  104/ml) were cul- 
tured in small magnetic culture dishes (1,800 gauss) in 5% CO2 
in air at 37~  The basic culture medium contained 10% FCS (Flow 
Laboratories, Rockville, MD),  2 ng/ml basic bovine flbrobhst 
growth factor (FGF) (Sigma Chemical Co., St. Louis, MO), 50 
ng/ml human rGM-CSF (Genzyme Corp., Boston, MA), 2 U/ml 
riD2 (Takeda Pharmaceutical Co., Osaka, Japan), and 20 ng/ml 
human rib5 (Santory Co., Osaka, Japan). After 2 wk, BMST were 
removed from the plastic surface. The BMST in suspension were 
again loaded on 40% Percoll gradients, and were purified by col- 
lecting cells from the upper fraction. To obtain sufficient  numbers 
of cells, the purified BMST (104/ml) were cultured for another 4 
wk (6 wk in total) in the presence of the same concentrations of 
the cytokines  in the mild magnetic force (400 gauss) system. About 
75% of the culture medium was renewed every week. Superua- 
tants of the BMST culture (BMST-sup) were coUected, filtered, 
and stored for the culture of LLC. 
The purified lymphoid progenitors were cultured in the pres- 
ence of 10% BMST-sup and the cytokine cocktail. After 2 wk, 
the cells yielded many clusters in the culture system with higher 
levels of  magnetic force (1,800 gauss). Since  the cultured cells formed 
tight cell aggregates, it was difficult to obtain LLC as a single-cell 
suspension. Cell cloning in a cluster form was performed by the 
limiting dilution method (0.3 cluster/well) using a feeder layer of 
preseeded BMST, BMST-sup, and the cytokines in 96-well culture 
plates. After 2 wk (4 wk after the initial culture), the growing 
LLC were selected based on positive CD3, WT31,  and TCR-/~I 
staining. After 4 wk (8 wk of culture in total), TCR-~/~ § T-LLC 
and  TCR-3,/# +  T-LLC were expanded using  24-well culture 
plates. They were further cultured in large culture dishes (100 x 
15 mm) on BMST in the presence of the cytokines. After 2-4 wk 
(10-12 wk in total), LLC were collected at 4-d intervals, and they 
were processed for phenotypic, in situ hybridization, and killer ac- 
tivity assays. 
Phenotypic Analysis.  Phenotypic  analyses  of surface  antigens  were 
performed on a FACStar  |  flow cytometry system (Becton Dick- 
inson Monoclonal Center, Mountain View, CA). Immunofluores- 
cence microscopy was also employed for the examination of intra- 
cellular immunostaining. A panel of mAbs and polyclonal  Abs were 
used for the analyses: CD3(Leu-4), CD8(Leu-2a), and TCR-cg/B 
(anti-TCg-l:  WT31) from Becton Dickinson Monoclonal Center; 
TCR-34~(~TCS1), TCR-~/B(3F1),  TCR-3,/~(TCS-81), ~Vl(a) 
(V81), and cSV2(a)(V82) from T Cell Science, Inc. (Cambridge, 
MA). Cells (10  ~) were incubated with appropriately diluted mAbs 
(1:40 for most Abs) for 30 min at 4~  washed twice, and incubated 
with a  1:40 dilution  of affinity-purified goat  anti-mouse  IgG- 
F(ab')2-FITC (Cappel Laboratories, Cochranville, PA). After wash- 
ing twice, the cells were resuspended in 1-ml PBS with 5% FCS 
and processed for cytometry. Cytospin slides were fixed  and stained 
with anti-CD3 for 30 min and 5-10 Izl of peroxidase-conjugated 
F(ab')2 fragment of anti-gnat, -rabbit,  or -mouse Ig(s) on ice for 
30 min. 
In Situ Hybridization.  The in situ hybridization  detection system 
(Bethesda Research Laboratories, Gaithersburg,  MD) was employed. 
The hybridization was performed using a biotin-labeled CB1 (22) 
constant region RNA probe (kindly provided by Dr. T. W. Mak, 
Toronto, Canada), and a TCR-C~I (23) DNA probe (synthesized 
by using a DNA synthesizer according to the map). 
Killer Activity Assay.  The killer activity of LLC was evaluated 
against PHA-activated  blastoid T cells (PHA-P: 0.1%) of the mother, 
father and siblings, according  to previous  reports (2, 3). For blocking 
experiments, target cells were treated with anti-HLA panel Abs 
(Fuji Biomaterials  Laboratory, Tokyo,  Japan). LLC and target cells 
were suspended in 0.2 ml of culture medium in each well of 
microplates in triplicate. The plates were centrifuged at 200 g for 
5 rain, and incubated for 4 h at 37~  From the radioactivity in 
0.1 ml of supernatant, percent specific  lysis was calculated by the 
following formula: Percent specific lysis =  100  x  (Experimental 
cpm -  medium control cpm)/(Maximum release  cpm -  medium 
control cpm). The maximal count was determined by disrupting 
the target cells in 1.25% saponin solution (Wako Pure Chemicals, 
Osaka, Japan), and amounted to more than 90% of the control 
radioactivity taken up by the target cells. The spontaneous SlCr- 
release from the target cells was <20%  of the maximal release. 
Results 
Fetal Liver LLC Cultured on BMST.  Fig. 1 shows the HLA 
typing of three family pedigrees.  We failed to analyze HLA 
in one family (F617;  8 wk). To define the involvement of 
HLA antigens, we selected families that consisted of three 
to four siblings. 
As for the fetal liver TCR-3,//~ LLC grown on fetal BMST, 
there were 23 clusters/weU in F617(8 wk), 184 dusters/well 
in F608(9.5  wk), 106 clusters/well in F612(10 wk), and 27 
dusters/well in F605(15 wk). These data are consistent with 
the finding that TCR-'y/~  + cells are prominent at around 
10 wk of gestation in the fetal liver (10). The clusters  were 
coUected and mixed together. Sufficient numbers of cells were 
obtainable  for  the  study  of  their  surface  antigens,  in- 
tracytoplasmic antigens, and for in situ hybridization. 
Cellular  Characteristics of the Fetal LLC.  FACS  |  profiles 
of TCR-q,/$-associated antigens on the LLC are shown in 
Fig. 2. F608(9.5  wk), F612(10 wk), and F605(15 wk) fetal 
liver LLC were studied for the expression of TCR-q,/& V~I, 
and V/~2. All of the six liver LLC lines were TCR-'y/~ +, 
consisting of a single population of brightly staining cells. 
However, there were both dimly and brightly staining V$1 + 
and V52 + ceils. As shown in Fig.  3,  all of the established 
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Figure 1.  HLA typing  of three family  pedigrees. (F) 
Father. (M) Mother. (Dotted squares) Fetus. (Open  squares 
in the haplotype  designations)  Unshared  haplotypes  be- 
tween the fetus and the mother. 
LLC lines showed almost the same pattern of  CD3-cyto, CD3, 
TCR-?/(~ and TCR-C&I positivity. All of them were nega- 
tive for CD4, TCR-(x/3  and TCR-C/91. There was a wide 
variation among them in the expression  of CD8, V~l, and 
V(~2. Two of the CD8 + LLC clones,  one in F612(10 wk) 
and the other in F605(15 wk), showed potent killer activity 
as described in the following section. It is interesting that 
all of the F617(8 wk) LLC lines  were V#2 +, but none of 
them expressed V(~I. In contrast, all of the F612(10 wk) and 
F605(15 wk) LLC lines were positive for V#I but negative 
for V~2.  Thus, there were no TCR-(x/fl + T  cells in these 
six LLC lines, and V~2 + and V~I + cells did not coexist in 
a single line. These data suggest that V~2 + cells are predom- 
inant at around 8 wk of gestation, and V~I + cells appear 
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Figure 5.  Specificity  of the killer activities 
of fetal liver T-LLC. Killer activities of fetal 
killer T6 T-LI.C against the maternal, paternal, 
and  sibling PHA-blasts. The  maternal Ab 
blocking was performed  by the addition of 1:50 
diluted anti-HLA Abs. 
in parallel with the development of thymus at around 9 wk 
of gestation  (14). 
As shown in Fig. 3, in situ hybridization showed that all 
of the  established  LLC lines  were positive  for TCR-CSl 
mRNA. 
Killer Activity of Cloned Fetal LLC.  Fig. 4 shows the cyto- 
toxic  potential  of fetal  liver  TCR-ot/B + LLC  and  TCR- 
?/d} + LLC against  maternal  PHA-activated T  cells.  Six of 
the TCR-qr/8 + liver T-LLC lines (6/24) from three fetuses 
had cytotoxic activity against the respective maternal PHA- 
induced target ceils:  two of F608 TCR-y/~ + , V82 + LLC, 
two  of F612  TCR-3,/5 + ,  V51 +  LLC,  and  two  of F605 
TCR-'y/8 + , V81 + LLC. The levels of CTL activity varied 
widely  among  the  lines:  the  lowest  was  in  V52 +  F608 
T~-22, and the highest was in V~}I  + F605 T&14. The V82 + 
F608 T&16 ceils with lower levels of CTL activity were fur- 
ther cultured for 4 wk, and again assayed for CTL activity. 
The activity levels did not increase (+  2%). In contrast, the 
VS1 + F612 T&ll  cells showed increased levels of CTL ac- 
tivity (+  20%) after culture for another 4 wk. These data 
indicate that CTL activity of V82 + LLC is generally lower 
than  that  of VS1 + LLC,  and that  two of the most  active 
LLC are CD8 + . Five of TCR-ot/~ + T-LLC lines (5/24) had 
no cytotoxic activity against PHA-activated maternal T cells. 
However, after addition of IFN-3, into these LLC, CTL ac- 
tivity  appeared  in  two  of the  TCR-c~//~ +  LLC  (data  not 
shown). 
It was interesting to determine whether or not these TCR- 
3,/5 + T-LLC had specificity for the maternal HLA antigens. 
For this purpose,  three TCR-'y/5 § T-LLC lines with high 
levels of CTL activity were selected, and their CTL specificities 
were analyzed using PHA-activated T  cells of the mother, 
father, and siblings as targets (Fig.  5). F608(HLA-A, -B, and 
-C) apparently recognizes the maternal  D  haplotype,  since 
specific cytotoxicity was observed with maternal(HLA: C and 
D) (Fig.  1) and sibling(C1; HLA: B and D) targets, but not 
with target cells from another sibling(C2;  HLA: A and C) 
or the father  (HLA: A  and B). Similarly,  F612 recognizes 
the maternal C haplotype, and F605 recognizes the maternal 
D haplotype in the respective families (Figs.  1 and 5). In each 
case, the maternal haplotype recognized represents an alloan- 
tigen for the proband,  from which the fetal liver LLC line 
was derived.  In the next experiment,  the CTL activity of 
the T-LLC against the maternal T cells was shown to be com- 
pletely blocked by the addition of antimatemal HLA-A and -B 
Abs (Fig. 5). These data suggest that fetal liver TCR-T/8 + 
T-LLC are specific for maternal T cells, and that CD8 + lines 
have high levels  of the killer  activity. 
Discussion 
Several mAbs have been developed to identify TCR-'y/~ 
expressing cells (24, 25). Some mAbs used in this study, such 
as b'Vl(a)  and 5V2(a), can recognize variable gene-encoded 
epitopes and delineate subsets of TCR-7/8 cells. Other mAbs, 
such as TCR-81, are reactive with all TCR-y/~5 cells, which 
suggests that  they are directed against  a C-encoded frame- 
work region. The availability of these mAbs has recently al- 
lowed the phenotype and tissue distribution of TCR-3,/b ceils 
to be defined. In humans,  about 4% of CD3 + cells express 
TCR-3~/~ in the fetal and postnatal thymus, peripheral blood, 
and lymphoid organs  (24,  25).  The maximum  percentage 
of TCR-3,/8 + , CD3 + cells, about 10%, can be found in the 
fetal thymus at 9 wk of gestation (14). TCR-7/8 + cells can 
recognize Ag in a MHC-restricted manner (7), undergo TCR- 
mediated cell activation (8), and participate in immune sur- 
veillance at epithelial cell surfaces (9). However, the function 
of fetal TCR-'y/8 + , CD3 + cells still remains to be examined 
because of the difficulty of obtaining sufficient numbers of 
such cells from the early human fetal lymphoid tissues. To 
overcome this problem, we have used a magnetic culture system 
for expanding  the original  cells. 
In recent years, we have presented one of the possible mech- 
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tack,  in which T  lymphocytotoxic human  fetal antibodies 
(TLFA)  act  to eliminate  alloreactive maternal  T  cells.  We 
identified two types of Abs reactive with  the T  and killer 
T  cells in maternal-fetal mixed lymphocyte cultures (2, 3). 
These two Ab specificities  are closely associated with MHC 
class I antigens. However, the mechanism for protecting the 
fetus from maternal immunologic rejection is probably mul- 
tifactorial.  We have used X-chromosomal analysis in a male 
fetus to demonstrate that maternal T cells can attack the fetus 
at the initiation  of gestation.  In the previous studies (1-3) 
however, we failed to expand fetal killer T  cells that could 
destroy the invading  maternal  T  cells. 
In the present study, we have established fetal TCR-3,/~ + 
T cell lines and have examined their cytotoxic potential. The 
cytotoxic assays demonstrate that fetal liver TCR-3,/~ + cells 
can be killer T cells for the maternal T cells, and the targets 
are maternal  alloantigens  (probably class  I).  A  straightfor- 
ward possible mechanism  for eliciting fetal T-LLC against 
the maternal immunologic attacks can be envisioned. If the 
haplotypes of the family members are represented as a father 
(a, b), a mother (c, d), and a fetus (b, d) then the maternal 
T cells share HLA molecules (d) with fetal determinants. How- 
ever, fetal T-LLC specific for (c) can react with the invading 
maternal  T  cells.  Actually, in our cytotoxic assay, three of 
the fetal TCR-y/8 + T-LLC clones showed specificity for the 
maternal  (c)  determinants. 
It  has  been  reported  that  pre-T(CD2 +,  cyto-CD3 +, 
CD7 +) cells migrate into the thymus where these immature 
lymphocytes mature into V61 + cells,  and then  into V82 + 
cells (10, 11, 26, 27). V82 + cells then disperse into lymphoid 
organs and finally appear in the peripheral blood. In this re- 
spect, all of the F608(8 wk) liver T-LLC consisted of V82 + 
cells in our study. The appearance of V82 + cells at 8 wk of 
gestation in fetal liver before the development of the thymus 
at around 9 wk of gestation (14), suggests that the liver may 
be another  maturation  organ  for V82 + cells. 
The mother obviously recognizes the fetus as nonself, and 
the fetus may protect itself from the maternal immunologic 
attack  by eliciting  TLFA  as  a  humoral  factor,  and  TCR- 
y/8 + T cells as a cellular factor.  It is also important  to take 
into account the influence of various hormones  and other 
barrier mechanisms of the placenta, as well as immunologic 
mechanisms  in the feto-maternal  interaction. 
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